Processing

Please wait...

Settings

Settings

Goto Application

1. EA201591686 - ПИРИДИНИЛЬНЫЕ И КОНДЕНСИРОВАННЫЕ ПИРИДИНИЛЬНЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛОНА

Office
Eurasian Patent Organization
Application Number 201591686
Application Date 10.03.2014
Publication Number 201591686
Publication Date 30.12.2015
Grant Number 028584
Grant Date 29.12.2017
Publication Kind B1
IPC
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
CPC
A61K 31/4375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4375the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4725
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
Applicants ТАКЕДА ФАРМАСЬЮТИКАЛ КОМПАНИ ЛИМИТЕД
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors Лоусон Джон Дэвид
Сабат Марк
Скора Николас
Смит Кристофер
Ву Пхонг Х.
Ван Хайся
LAWSON John, David
SABAT Mark
SCORAH Nicholas
SMITH Christopher
VU Phong, H.
WANG Haxia
Agents Медведев Валерий Николаевич
Medvedev Valery, N.
Priority Data 61/776,445 11.03.2013 US
Title
(RU) ПИРИДИНИЛЬНЫЕ И КОНДЕНСИРОВАННЫЕ ПИРИДИНИЛЬНЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛОНА
Abstract
(RU)

Описаны соединения формулы 1,

или их фармацевтически приемлемые соли, где R1, R2, R3 и R4 описаны в тексте. Настоящее изобретение относится также к материалам и способам получения соединений формулы 1, к фармацевтическим композициям, которые содержат указанные соединения, а также к их применению для лечения реакций гиперчувствительности типа I, аутоиммунных заболеваний, воспалительных расстройств, рака, незлокачественных пролиферативных расстройств и других патологических состояний, связанных с BTK.